Camurus: A Swedish Biotech Success Story - Redeye

Redeye initiates coverage of Camurus, a biotech company that made it from start-up to large cap, currently profitable with a cumulative annual growth rate of 54% for 2020–2024 in the opioid use disorder market, a still strong outlook and a blockbuster pipeline.

Länk till analysen i sin helhet: https://www.redeye.se/research/1096520/a-swedish-biotech-success-story?utm_source=finwire&utm_medium=RSS